FLOW CYTOMETRIC ANALYSIS OF PRIMARY AND METASTATIC BLADDER-CANCER

被引:22
|
作者
BADALAMENT, RA
OTOOLE, RV
KEYHANIROFAGHA, S
BARKLEY, C
KENWORTHY, P
ACCETTA, P
WISE, H
PEREZ, JF
DRAGO, JR
机构
[1] RIVERSIDE METHODIST HOSP, DEPT PATHOL, COLUMBUS, OH 43214 USA
[2] DOCTORS HOSP, DEPT SURG, DIV UROL, COLUMBUS, OH USA
来源
JOURNAL OF UROLOGY | 1990年 / 143卷 / 05期
关键词
D O I
10.1016/S0022-5347(17)40134-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A total of 22 patients with high grade P2-4N+ transitional cell carcinoma of the bladder underwent flow cytometric analysis of nuclei obtained from paraffin embedded specimens from the primary (bladder) and metastatic (lymph node) sites. Tumor heterogeneity was defined as polyclonal aneuploidy of the primary tumor (not identified in the population studied) or as a difference in the deoxyribonucleic acid index of the primary and metastatic sites of 0.20 or more (8 patients). With these criteria 8 patients (36%) had heterogeneous tumors and 14 (64%) had homogeneous tumors. The median survival of 14 patients with aneuploid and 8 with diploid primary tumors was 17.5 and 8.0 months, respectively (p equals 0.08, Lee-Desu test). When patient survival was compared to the ploidy of the metastatic site, or in patients with diploid primary and metastatic lesions versus deoxyribonucleic acid aneuploidy at either the primary and/or metastatic site, the aneuploid tumors had a longer survival but this difference was not significant (p equals 0.13 and 0.23, respectively). Our study demonstrates the value of flow cytometry to identify primary metastatic tumor heterogeneity. It also suggests that the presence of metastasis may be a more important factor to define the biological potential of transitional cell carcinoma than is deoxyribonucleic acid ploidy.
引用
收藏
页码:912 / 916
页数:5
相关论文
共 50 条
  • [31] FLOW CYTOMETRIC DEMONSTRATION OF SHARED ANTIGENS BETWEEN HUMAN BLADDER-CANCER CELLS AND NORMAL HOST MACROPHAGES
    DEVONEC, M
    HIJAZI, A
    BRINGUIER, PP
    DUTRIEUXBERGER, N
    PERRIN, P
    REVILLARD, JP
    EUROPEAN UROLOGY, 1989, 16 (01) : 57 - 62
  • [33] PATTERN OF URINARY SYMPTOMS IN PATIENTS WITH METASTATIC BLADDER-CANCER
    COHEN, JM
    PERSKY, L
    RESNICK, MI
    JOURNAL OF UROLOGY, 1986, 136 (03): : 586 - 588
  • [34] THE PROGNOSTIC-SIGNIFICANCE OF DUAL PARAMETER FLOW CYTOMETRIC ANALYSIS OF PRIMARY AND METASTATIC BREAST-CANCER
    LAWRY, J
    ROGERS, K
    BRITISH JOURNAL OF CANCER, 1987, 56 (02) : 213 - 213
  • [35] PHASE-II TRIALS IN METASTATIC BLADDER-CANCER
    HALL, RR
    CALVERT, AH
    DESTAVOLA, B
    FREEDMAN, LS
    GOODMAN, S
    KAYE, S
    ROGERS, ACN
    LANCET, 1986, 1 (8488): : 1028 - 1028
  • [36] MANAGEMENT OF PRIMARY BLADDER-CANCER BY A MULTIDISCIPLINARY TEAM
    COLLINS, WE
    CATTON, GE
    HUSSEY, A
    BAKER, RG
    LAST, JM
    CANADIAN JOURNAL OF SURGERY, 1979, 22 (05) : 431 - 434
  • [37] APPENDICEAL CARCINOMA MIMICKING PRIMARY BLADDER-CANCER
    HENRY, R
    BRACKEN, RB
    AYALA, A
    JOURNAL OF UROLOGY, 1980, 123 (04): : 590 - 591
  • [38] THE CLINICOPATHOLOGICAL FEATURES OF METASTATIC SUPERFICIAL PAPILLARY BLADDER-CANCER
    MATTHEWS, PN
    MADDEN, M
    BIDGOOD, KA
    FISHER, C
    JOURNAL OF UROLOGY, 1984, 132 (05): : 904 - 906
  • [39] SUBSEQUENT PRIMARY CANCERS FOLLOWING BLADDER-CANCER
    SALMINEN, E
    PUKKALA, E
    TEPPO, L
    PYRHONEN, S
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (03) : 303 - 307
  • [40] QUANTIFICATION OF CELL KINETIC CHARACTERISTICS USING FLOW CYTOMETRIC MEASUREMENTS OF DEOXYRIBONUCLEIC-ACID AND BROMODEOXYURIDINE FOR BLADDER-CANCER
    TACHIBANA, M
    DEGUCHI, N
    JITSUKAWA, S
    BABA, S
    HATA, M
    TAZAKI, H
    JOURNAL OF UROLOGY, 1991, 145 (05): : 963 - 967